Case Study: Nitrosamine Risk Assessment for a Proton Pump Inhibitor Seeking ANDA Approval
Introduction A comprehensive Nitrosamine Risk Assessment for a Proton Pump Inhibitor seeking Abbreviated New Drug Application (ANDA) approval requires a […]
Generic Drug Development for Inhaled Drug Products: MDI, DPI, and Nasal Spray ANDA Challenges at a CDMO
Introduction: Generic Drug Development for Inhaled Drug Products requires a development strategy that connects formulation science, device engineering, analytical characterization,
Sequence Confirmation Services for Synthetic Therapeutic Peptides: From Research Batches to GMP Lots
Introduction Sequence Confirmation Services for Synthetic Therapeutic Peptides provide definitive verification of the primary amino acid sequence, terminal modifications, and
Automation in Peptide-Oligonucleotide Conjugate Synthesis
Introduction: Automation in Peptide-Oligonucleotide Conjugate Synthesis is becoming increasingly important as researchers seek more reproducible and scalable ways to manufacture
Automation in Peptide-Oligonucleotide Conjugate Synthesis Read More »
Peptide-Oligonucleotide Conjugate Drug Product Formulation Services: From Bulk API to Injectable Drug Product
Introduction Peptide-Oligonucleotide Conjugate Drug Product Formulation Services address the complex development transition between bulk active pharmaceutical ingredient (API) bioconjugation and
Next-Generation Oligonucleotide Chemistries in Peptide-Oligonucleotide Conjugates Design: LNA, PNA, and Morpholino Modifications
Introduction Peptide-oligonucleotide conjugates depend on Next-Generation Oligonucleotide Chemistries to address the limitations associated with native enzymatic degradation, inadequate cellular permeability,
Case Study: Generic Topical Semisolid ANDA — Formulation Equivalence, Dissolution, and Q1/Q2 Sameness
Introduction Demonstrating bioequivalence for a Generic Topical Semisolid ANDA requires a comprehensive assessment of qualitative (Q1), quantitative (Q2), and structural
What Regulatory Pathway Do Generic Peptide Drugs Follow — ANDA, 505(b)(2), or BLA?
Introduction Selecting the appropriate Generic Peptide Regulatory Pathway—whether an Abbreviated New Drug Application (ANDA) under Section 505(j), a hybrid New
What Regulatory Pathway Do Generic Peptide Drugs Follow — ANDA, 505(b)(2), or BLA? Read More »
Impurity Control Strategies Under ICH Q3A and Q3B for Generic Drug ANDA Submissions
Introduction Executing compliant Impurity Control Strategies Under ICH Q3A and Q3B requires establishing scientific and toxicological parity with the Reference
Impurity Control Strategies Under ICH Q3A and Q3B for Generic Drug ANDA Submissions Read More »
Case Study: Generic Ophthalmic Suspension ANDA Development — Sterile Fill, Container Closure, and BE Strategy
Introduction Executing Generic Ophthalmic Suspension ANDA Development requires a coordinated technical strategy that integrates qualitative and quantitative sameness (Q1/Q2), structural